Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025
AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadershi...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Resistant Cases
KEYTRUDA Ovarian Cancer Treatments Gain FDA Nod
KEYTRUDA ovarian cancer treatments now include FDA-approved regimens of KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each with paclitaxel ±...
South Africa Health Reform: Navigating Innovations and Challenges for 2026
South Africa Health Reform: Contrasts in 2026 Public Health Agenda
South Africa health reform defines the 2026 public health landscape as a mix of breakthroughs like HIV prevention injections and AI-driven TB diagnos...